233 related articles for article (PubMed ID: 28659174)
1. CRISPR/Cas9 targeting of GPRC6A suppresses prostate cancer tumorigenesis in a human xenograft model.
Ye R; Pi M; Cox JV; Nishimoto SK; Quarles LD
J Exp Clin Cancer Res; 2017 Jun; 36(1):90. PubMed ID: 28659174
[TBL] [Abstract][Full Text] [Related]
2. Human GPRC6A Mediates Testosterone-Induced Mitogen-Activated Protein Kinases and mTORC1 Signaling in Prostate Cancer Cells.
Ye R; Pi M; Nooh MM; Bahout SW; Quarles LD
Mol Pharmacol; 2019 May; 95(5):563-572. PubMed ID: 30894404
[TBL] [Abstract][Full Text] [Related]
3. GPRC6A regulates prostate cancer progression.
Pi M; Quarles LD
Prostate; 2012 Mar; 72(4):399-409. PubMed ID: 21681779
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.
Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E
J Hematol Oncol; 2022 Oct; 15(1):145. PubMed ID: 36224639
[TBL] [Abstract][Full Text] [Related]
5. GPRC6A: Jack of all metabolism (or master of none).
Pi M; Nishimoto SK; Quarles LD
Mol Metab; 2017 Feb; 6(2):185-193. PubMed ID: 28180060
[TBL] [Abstract][Full Text] [Related]
6. Humanized GPRC6A
Pi M; Xu F; Ye R; Nishimoto SK; Kesterson RA; Williams RW; Lu L; Quarles LD
Sci Rep; 2020 Jul; 10(1):11143. PubMed ID: 32636482
[TBL] [Abstract][Full Text] [Related]
7. TNFAIP3 is required for FGFR1 activation-promoted proliferation and tumorigenesis of premalignant DCIS.COM human mammary epithelial cells.
Yang M; Yu X; Li X; Luo B; Yang W; Lin Y; Li D; Gan Z; Xu J; He T
Breast Cancer Res; 2018 Aug; 20(1):97. PubMed ID: 30111373
[TBL] [Abstract][Full Text] [Related]
8. Explaining Divergent Observations Regarding Osteocalcin/GPRC6A Endocrine Signaling.
Pi M; Nishimoto SK; Darryl Quarles L
Endocrinology; 2021 Apr; 162(4):. PubMed ID: 33474566
[TBL] [Abstract][Full Text] [Related]
9. GPCR6A Is a Molecular Target for the Natural Products Gallate and EGCG in Green Tea.
Pi M; Kapoor K; Ye R; Smith JC; Baudry J; Quarles LD
Mol Nutr Food Res; 2018 Apr; 62(8):e1700770. PubMed ID: 29468843
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a role of GPRC6A in prostate cancer metastasis based on case-control and in vitro analyses.
Liu M; Zhao YY; Yang F; Wang JY; Shi XH; Zhu XQ; Xu Y; Wei D; Sun L; Zhang YG; Yang K; Qu YC; Wang X; Liang SY; Chen X; Zhao CX; Zhu L; Tang L; Zheng CG; Yang Z
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2235-48. PubMed ID: 27338047
[TBL] [Abstract][Full Text] [Related]
11. Chemokine CXCL3 mediates prostate cancer cells proliferation, migration and gene expression changes in an autocrine/paracrine fashion.
Xin H; Cao Y; Shao ML; Zhang W; Zhang CB; Wang JT; Liang LC; Shao WW; Qi YL; Li Y; Zhang ZY; Yang Z; Sun YH; Zhang PX; Jia LL; Wang WQ
Int Urol Nephrol; 2018 May; 50(5):861-868. PubMed ID: 29524043
[TBL] [Abstract][Full Text] [Related]
12. GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo.
Pi M; Wu Y; Quarles LD
J Bone Miner Res; 2011 Jul; 26(7):1680-3. PubMed ID: 21425331
[TBL] [Abstract][Full Text] [Related]
13. GPRC6A mediates the non-genomic effects of steroids.
Pi M; Parrill AL; Quarles LD
J Biol Chem; 2010 Dec; 285(51):39953-64. PubMed ID: 20947496
[TBL] [Abstract][Full Text] [Related]
14. Osteocalcin Induces Proliferation via Positive Activation of the PI3K/Akt, P38 MAPK Pathways and Promotes Differentiation Through Activation of the GPRC6A-ERK1/2 Pathway in C2C12 Myoblast Cells.
Liu S; Gao F; Wen L; Ouyang M; Wang Y; Wang Q; Luo L; Jian Z
Cell Physiol Biochem; 2017; 43(3):1100-1112. PubMed ID: 28977794
[TBL] [Abstract][Full Text] [Related]
15. rs2274911 polymorphism in GPRC6A associated with serum E2 and PSA in a Southern Chinese male population.
Qi N; Chen Y; Zeng Y; Bao M; Long X; Guo Y; Tan A; Gao Y; Zhang H; Yang X; Hu Y; Mo Z; Jiang Y
Gene; 2020 Dec; 763():145067. PubMed ID: 32827681
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
Batır MB; Şahin E; Çam FS
Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
[TBL] [Abstract][Full Text] [Related]
17. Murine GPRC6A Mediates Cellular Responses to L-Amino Acids, but Not Osteocalcin Variants.
Rueda P; Harley E; Lu Y; Stewart GD; Fabb S; Diepenhorst N; Cremers B; Rouillon MH; Wehrle I; Geant A; Lamarche G; Leach K; Charman WN; Christopoulos A; Summers RJ; Sexton PM; Langmead CJ
PLoS One; 2016; 11(1):e0146846. PubMed ID: 26785252
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Gene Editing by CRISPR-Cas9 of miR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer.
Camargo JA; Viana NI; Pimenta R; Guimarães VR; Dos Santos GA; Candido P; Ghazarian V; Romão P; Silva IA; Birbrair A; Srougi M; Nahas WC; Leite KR; Trarbach EB; Reis ST
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834295
[TBL] [Abstract][Full Text] [Related]
19. Prostate transglutaminase (TGase-4) antagonizes the anti-tumour action of MDA-7/IL-24 in prostate cancer.
Ablin RJ; Kynaston HG; Mason MD; Jiang WG
J Transl Med; 2011 Apr; 9():49. PubMed ID: 21524313
[TBL] [Abstract][Full Text] [Related]
20. Expression of LDL-A module of relaxin receptor in prostate cancer cells inhibits tumorigenesis.
Feng S; Agoulnik AI
Int J Oncol; 2011 Dec; 39(6):1559-65. PubMed ID: 21842120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
